• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Novel Substituted Lactams as 5‑HT1A Agonists for Treating Neuropsychiatric Diseases.新型取代内酰胺类化合物作为5-HT1A激动剂用于治疗神经精神疾病。
ACS Med Chem Lett. 2025 May 16;16(6):950-951. doi: 10.1021/acsmedchemlett.5c00270. eCollection 2025 Jun 12.
2
Novel Substituted Pyrazoles as 5‑HT1A Agonists for Treating Neuropsychiatric Diseases.新型取代吡唑类化合物作为5-羟色胺1A受体激动剂用于治疗神经精神疾病
ACS Med Chem Lett. 2025 Jun 3;16(6):978-979. doi: 10.1021/acsmedchemlett.5c00306. eCollection 2025 Jun 12.
3
Novel Lactams as SARM1 Inhibitors for Treating Axonal Degeneration.新型内酰胺类化合物作为治疗轴突退变的SARM1抑制剂
ACS Med Chem Lett. 2025 May 9;16(6):931-932. doi: 10.1021/acsmedchemlett.5c00241. eCollection 2025 Jun 12.
4
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.新型色胺化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2025 Feb 13;16(3):373-374. doi: 10.1021/acsmedchemlett.5c00047. eCollection 2025 Mar 13.
5
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.新型麦角灵化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
6
Novel Piperidine Substituted Pyrazolopyrimidine Derivatives as SGK1 Inhibitors for Treating Cardiovascular Diseases.新型哌啶取代的吡唑并嘧啶衍生物作为治疗心血管疾病的SGK1抑制剂
ACS Med Chem Lett. 2025 Apr 25;16(5):762-763. doi: 10.1021/acsmedchemlett.5c00217. eCollection 2025 May 8.
7
Novel Substituted Cyclic Compounds as SLC6A19 Inhibitors for Treating Phenylketonuria and Other Amino Acidurias.作为治疗苯丙酮尿症和其他氨基酸尿症的SLC6A19抑制剂的新型取代环状化合物
ACS Med Chem Lett. 2025 Apr 11;16(5):734-735. doi: 10.1021/acsmedchemlett.5c00177. eCollection 2025 May 8.
8
Novel Substituted Benzimidazole Compounds as TLR9 Inhibitors for Treating Fibrotic Diseases, Particularly Idiopathic Pulmonary Fibrosis.新型取代苯并咪唑化合物作为用于治疗纤维化疾病，特别是特发性肺纤维化的TLR9抑制剂
ACS Med Chem Lett. 2024 Oct 16;15(11):1804-1805. doi: 10.1021/acsmedchemlett.4c00473. eCollection 2024 Nov 14.
9
Novel Pyrrolidinone Urea Compounds as FPR2 Agonists for Treating Atherosclerosis and Heart Failure.新型吡咯烷酮脲化合物作为治疗动脉粥样硬化和心力衰竭的FPR2激动剂
ACS Med Chem Lett. 2024 Nov 14;15(12):2093-2094. doi: 10.1021/acsmedchemlett.4c00536. eCollection 2024 Dec 12.
10
Novel Pyrrolopyridine Compounds as 5-HT2A Agonists for Treating Mental Illnesses.作为用于治疗精神疾病的5-HT2A激动剂的新型吡咯并吡啶化合物。
ACS Med Chem Lett. 2025 Jan 23;16(2):202-203. doi: 10.1021/acsmedchemlett.5c00019. eCollection 2025 Feb 13.

本文引用的文献

1
5-HT receptors: Pharmacology and functional selectivity.5-羟色胺受体：药理学与功能选择性
Pharmacol Rev. 2025 Jul;77(4):100059. doi: 10.1016/j.pharmr.2025.100059. Epub 2025 Apr 23.
2
The evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity.N，N-二甲基色胺的演变：从代谢途径到脑连接性
Psychopharmacology (Berl). 2025 Apr 11. doi: 10.1007/s00213-025-06777-z.
3
Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications.致幻剂诱导的神经可塑性：全面综述及临床意义探讨
Brain Sci. 2025 Jan 25;15(2):117. doi: 10.3390/brainsci15020117.
4
Novel Pyridine Derivatives as 5-HT2A Agonists for Treating Psychiatric Disorders.新型吡啶衍生物作为治疗精神疾病的5-HT2A激动剂
ACS Med Chem Lett. 2025 Jan 8;16(2):192-193. doi: 10.1021/acsmedchemlett.4c00629. eCollection 2025 Feb 13.
5
Exploring DMT: Endogenous role and therapeutic potential.探索二甲基色胺：内源性作用及治疗潜力。
Neuropharmacology. 2025 May 1;268:110314. doi: 10.1016/j.neuropharm.2025.110314. Epub 2025 Jan 18.
6
Antidepressant and anxiolytic effects of activating 5HT2A receptors in the anterior cingulate cortex and the theoretical mechanisms underlying them - A scoping review of available literature.前扣带回皮层中5HT2A受体激活的抗抑郁和抗焦虑作用及其潜在理论机制——现有文献的综述
Brain Res. 2025 Jan 1;1846:149226. doi: 10.1016/j.brainres.2024.149226. Epub 2024 Sep 7.

新型取代内酰胺类化合物作为5-HT1A激动剂用于治疗神经精神疾病。

Novel Substituted Lactams as 5‑HT1A Agonists for Treating Neuropsychiatric Diseases.

作者信息

Sabnis Ram W

机构信息

Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Atlanta, Georgia 30309, United States.

出版信息

ACS Med Chem Lett. 2025 May 16;16(6):950-951. doi: 10.1021/acsmedchemlett.5c00270. eCollection 2025 Jun 12.

DOI:10.1021/acsmedchemlett.5c00270
PMID:40529073
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12169494/
Abstract

Provided herein are novel substituted lactams as 5-HT1A agonists, pharmaceutical compositions, use of such compounds in treating neuropsychiatric diseases and processes for preparing such compounds.

摘要

本文提供了作为5-羟色胺1A（5-HT1A）激动剂的新型取代内酰胺、药物组合物、此类化合物在治疗神经精神疾病中的用途以及制备此类化合物的方法。